We are pleased to announce the launch our Next Generation Sequencing panel for Solid tumours (Oncomine Focus assay).
This has been done in an attempt to improve and streamline our molecular pathology testing offering. As opposed to testing for single gene anomalies separately, next generation sequencing (NGS) technology allows for testing of multiple genes at one time. This increases cost efficiency and reduces the amount of tissue required, since only three scrolls of tissue are utilized, and all genes of interest are included in a single test.
The Oncomine Focus assay is designed to detect single nucleotide variants (SNVs), indels, copy number variants (CNVs) and gene fusions in DNA and RNA derived from FFPE tissue. 52 genes are analysed, including BRAF, EGFR, KRAS, NRAS, ALK, MET and ROS1
Solid Tumour NGS panel (Oncomine Focus)